Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium | Citedby Results | Acta Haematologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium

Acta Haematol (2019) 142 (4): 197–207.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape

Diletta Fontana
Giovanni Paolo Maria Zambrotta
Antonio Scannella
Rocco Piazza
Carlo Gambacorti-Passerini

Annals of Hematology (2024) 103 (5): 1561.

Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment‐free remission after failing the first attempt with imatinib: Treatment‐free Remission Accomplished by Dasatinib (TRAD) study

Maria Agustina Perusini
Igor Novitzky‐Basso
Eshetu G. Atenafu
Donna Forrest
Isabelle Bence‐Bruckler
Lynn Savoie
Mary‐Margaret Keating
Lambert Busque
Robert Delage
Anargyros Xenocostas
Elena Liew
Pierre Laneuville
Kristjan Paulson
Tracy Stockley
Jeffrey H. Lipton
Brian Leber
Dennis Dong Hwan Kim

British Journal of Haematology (2023) 203 (5): 781.

Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia

Guray Saydam
Ali Unal
Ibrahim Celalettin Haznedaroglu
Abdullah Hacihanifioglu
Ozgur Mehtap
Erdal Kurtoglu
Mesut Gocer
Mehmet Turgut
Engin Kelkitli
Memis Hilmi Atay
Nil Guler
Basak Unver Koluman
Mehmet Sonmez
Nergiz Erkut
Emin Kaya
Irfan Kuku
Mehmet Ali Erkurt
Gulsum Ozet
Funda Ceran
Fahri Sahin
Nur Soyer
Meliha Nalcaci
Mehmet Yilmaz
Sirac Bozkurt
Birkan Aver
Begum Ozdengulsun
Egemen Ozbilgili
Osman Ilhan

International Journal of Hematologic Oncology (2022) 11 (3)

Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views

Vashti N. M. F. Tromp
Lonneke Timmers
Leanne Koningen
Jeroen J. W. M. Janssen
Peter E. Westerweel
Inge G. P. Geelen
Jan de Jong
Jan J. Beckeringh
Christel C. L. M. Boons
Jacqueline G. Hugtenburg

Leukemia & Lymphoma (2021) 62 (3): 649.

Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta‐analysis of studies over the last ten years

Stéphanie Dulucq
Cyril Astrugue
Gabriel Etienne
François‐Xavier Mahon
Antoine Benard

British Journal of Haematology (2020) 189 (3): 452.

Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation

Elisa Diral
Silvia Mori
Laura Antolini
Elisabetta Abruzzese
Philipp Le Coutre
Bruno Martino
Ester Pungolino
Chiara Elena
Micaela Bergamaschi
Sarit Assouline
Eros Di Bona
Antonella Gozzini
Marcio Andrade-Campos
Fabio Stagno
Alessandra Iurlo
Alessandra Pirola
Diletta Fontana
Jessica Petiti
Maria Luisa Bonanomi
Patrizia Crivori
Rocco Piazza
Carmen Fava
Carlo Gambacorti-Passerini

Blood (2020) 136 (19): 2237.